Positive data from an ongoing Phase Ib study has impressed investors in Aptevo Therapeutics. Following a clinical update that includes a complete remission in an acute myeloid leukemia patient, the company stock shot up more than 46% in premarket trading to $9.52 per share.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,